Novo Nordisk ADR (NYSE: NVO)’s stock price has gone decline by -0.78 in comparison to its previous close of 124.02, however, the company has experienced a -3.00% decrease in its stock price over the last five trading days. The Motley Fool reported 2024-05-04 that The outlook for Pfizer’s experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
Novo Nordisk ADR (NYSE: NVO) has a price-to-earnings ratio that is above its average at 42.49x. The stock has a 36-month beta value of 0.42. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NVO is 3.34B, and at present, short sellers hold a 0.10% of that float. On May 06, 2024, the average trading volume of NVO was 4.91M shares.
NVO’s Market Performance
The stock of Novo Nordisk ADR (NVO) has seen a -3.00% decrease in the past week, with a -0.73% drop in the past month, and a 8.22% gain in the past quarter. The volatility ratio for the week is 2.18%, and the volatility levels for the past 30 days are at 1.88% for NVO. The simple moving average for the last 20 days is -2.01% for NVO’s stock, with a simple moving average of 16.14% for the last 200 days.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with BMO Capital Markets repeating the rating for NVO by listing it as a “Outperform.” The predicted price for NVO in the upcoming period, according to BMO Capital Markets is $163 based on the research report published on April 12, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see NVO reach a price target of $120. The rating they have provided for NVO stocks is “Overweight” according to the report published on January 23rd, 2024.
NVO Trading at -3.22% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.01% of loss for the given period.
Volatility was left at 1.88%, however, over the last 30 days, the volatility rate increased by 2.18%, as shares sank -2.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.18% lower at present.
During the last 5 trading sessions, NVO fell by -3.00%, which changed the moving average for the period of 200-days by +53.59% in comparison to the 20-day moving average, which settled at $125.43. In addition, Novo Nordisk ADR saw 18.95% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.45 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.37. The total capital return value is set at 0.82. Equity return is now at value 99.99, with 32.56 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at 3.47. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 45.41.
Currently, EBITDA for the company is 112.94 billion with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 15.46. The receivables turnover for the company is 3.87for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.70.
Conclusion
To sum up, Novo Nordisk ADR (NVO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
